In March 2009, a new antimicrobial drug ceftobiprol medocaril was registered on the American pharmaceutical market (Zeftera, company Janssen Pharmaceutica NV, Belgium, registration certificate number LSR-002180/09 of March 20, 2009) , which is currently the only representative of the fifth generation of cephalosporins and which has a unique β-lactam activity against the strains resistant to methicillin S. aureus.

Ceftobiprol has bactericidal activity against a wide range of pathogens - Gram-positive pathogens: S. aureus and coagulase-negative staphylococci, S. pneumoniae, E. faecalis, including strains resistant to commonly used antibiotics; Gram negative pathogens: H. influenzae, enterobacteria (except strains producing extended spectrum beta-lactamases - BLRS), certain isolates P. aeruginosa. The broadening of the spectrum of activity compared to cephalosporins of generations I-IV is due to a significant increase in the affinity of the ceftobiprol molecule for penicillin-binding proteins (PSB), including PSB-2a , characteristic of methicillin-resistant staphylococci.

Two randomized, double-blind, controlled clinical trials have demonstrated the high efficacy and favorable safety profile of ceftobiprol. The first study (n = 784) compared ceftobiprol (500 mg every 12 hours iv by 60-minute infusion) to vancomycin (1000 mg every 12 hours iv by 60-minute infusion) in patients with complicated infections skin and soft tissue. In the second (n = 828), ceftobiprol (500 mg every 8 hours as a 120-minute infusion) was compared to a combination of vancomycin (1000 mg every 12 hours IV as a 60-minute infusion) and ceftazidime (1000 mg every 8 hours in (as a 120-minute infusion) in the treatment of complicated infections of the skin and soft tissues, including patients with infected diabetic feet without concomitant osteomyelitis.

The drug is registered in the United States of America for use in the treatment of complicated infections of the skin and soft tissues, including patients with infected diabetic foot without concomitant osteomyelitis.

Ceftobiprol can be prescribed at a dose of 500 mg twice a day as a 60-minute iv infusion for complicated infections of the skin and soft tissues caused only by Gram-positive pathogens. For infectious polymicrobial lesions (gram (+) + gram (-)) or for infections caused by gram negative pathogens, as well as for patients with an infected diabetic foot, ceftobiprol should be administered at a dose of 500 mg every 8 hours as a 120 minute iv infusion. The recommended treatment time is 7 to 14 days.